versão impressa ISSN 1516-4446
Rev. Bras. Psiquiatr. vol.33 no.1 São Paulo mar. 2011 Epub 02-Jul-2010
Avaliação do ciclo claro e escuro no comportamento relacionado à ansiedade e à depressão em ratos de diferentes idades após tratamento crônico com hidrocloridrato de metilfenidato
Karin M. GomesI; Renan P. SouzaII; Cecília G. InácioI; Samira S. ValvassoriI; Gislaine Z. RéusI; Márcio R. MartinsI; Clarissa M. ComimI; João QuevedoI,III
ILaboratory of Neurosciences and National Institute for Translational Medicine (INCT-TM), Postgraduate Program in Health Sciences, Health Sciences Unit, Universidade do Extremo Sul Catarinense, Criciúma, SC, Brazil
IINeurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, ON, Canada
IIILaboratory of Translational Psychiatry, Research Center, Hospital São José, Criciúma, SC, Brazil
OBJECTIVE: Methylphenidate hydrochloride is the most widely used medication for treatment and management of attention-deficit hyperactivity disorder. However, the chronic effects of methylphenidate hydrochloride on anxiety- and depressive-like rat behaviors remain poorly investigated. In this context, the present study evaluated the effects of treatment with methylphenidate hydrochloride on anxiety- and depressive-like behaviors using young and adult rats during the light and the dark cycle.
METHOD: Male Wistar rats (25 or 60 days old) received a once-daily (in either the light or dark cycle) methylphenidate hydrochloride (2mg/kg) or saline intraperitoneal injection for 28 days. We performed elevated plus maze and forced swimming test two hours after the last injection.
RESULTS: The light/dark cycle was a significant factor in the anxiety-like behaviors; however, no significant interaction between all three factors (cycle, age and methylphenidate hydrochloride) was found. Nevertheless, we observed a nominally significant interaction between the light/ dark cycle and age in the forced swimming test.
CONCLUSION: Our results have shown that age and the light/dark cycle are more significant modulators of anxiety- and depressive-like behaviors than methylphenidate hydrochloride treatment.
Descriptors: Attention; Behavior; Anxiety; Rats, Wistar; Methylphenidate
OBJETIVO: Hidrocloridrato de metilfenidato é a medicação preferida para o tratamento e manutenção do transtorno de atenção e hiperatividade. No entanto, os efeitos do tratamento crônico com hidrocloridrato de metilfenidato em diferentes idades e ciclos sobre o comportamento relacionado à ansiedade e à depressão ainda não está claro. Neste contexto, o presente estudo teve como objetivo avaliar os efeitos do tratamento com hidrocloridrato de metilfenidato sobre o comportamento relacionado à ansiedade e à depressão em diferentes idades e no ciclo claro e escuro.
MÉTODO: Foram utilizados ratos Wistar machos jovens e adultos que receberam uma vez ao dia (ciclo claro e escuro) hidrocloridrato de metilfenidato (2mg/kg) ou salina com injeção intraperitoneal, durante 28 dias. Após duas horas da última injeção, os animais foram submetidos ao testes de labirinto em cruz elevada e natação forçada.
RESULTADOS: A fase do ciclo claro e escuro foi um fator significativo para o comportamento relacionado à ansiedade. Além disso, não houve interação significativa entre os ciclos claro e escuro, idade e metilfenidato no comportamento relacionado à ansiedade e à depressão, mas foi observada uma interação significativa entre ciclo claro e escuro e idade no teste de natação forçada.
CONCLUSÃO: Nossos resultados mostraram que a idade e o ciclo claro e escuro são moduladores significativos de ambos os comportamentos quanto do tratamento com hidrocloridrato de metilfenidato.
Descritores: Atenção; Comportamento; Ansiedade; Ratos Wistar; Metilfenidato
Attention-deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neuropsychiatric disorder in childhood, characterized by excessive levels of inattentiveness, impulsivity and hyperactivity. Most ADHD patients benefit from treatment with methylphenidate hydrochloride (MPH), which effectively reduces symptoms in up to 70% of child patients. Moreover, recognition that ADHD persists into adulthood has led to an increased use of MPD in adult patients.1 Age and circadian rhythms are modulators of MPH response in rats. 2 Biological rhythms, particularly circadian rhythms, are an essential part of the temporal order of living systems and their disruption has been related to some neuropsychiatric disorders.2
MPH has effects on behavioral tasks associated with anxiety and depressive symptoms, although the findings are controversial.2,3 It has been shown that drugs that can modulate anxiety-like symptoms, such as benzodiazepines, present age- and diurnal-dependent results in rats.4,5 Notably, antidepressants are known to affect the circadian timing system in rodents.5,6 Therefore, we hypothesized that the effects of MPH on the elevated plus maze (a test that can access anxiety-like behaviors) and the forced swimming test (a test that can access depressive-like behaviors) might be altered according to age and the light/dark cycle.
Young (postnatal day PD25; 75-85g) and adults (PD60; 250-300g) male Wistar rats obtained from our breeding colony were housed five to a cage with food and water available ad libitum and maintained on a 12-hour light/dark cycle (lights on at 7:00 a.m.). We performed the behavioral tasks during either the light (7:00-10:00a.m.) or the dark (7:00-10:00p.m) cycle. All experimental procedures were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and the Brazilian Society for Neuroscience and Behavior recommendations for animal care. The Ethics Committee of Universidade do Extremo Sul Catarinense approved this study before we conducted the experiments.
2. Drugs and treatments
Rats were divided into four groups: Saline-light; MPH-light; Saline-dark and MPH-dark (n = 30 per group; n = 15 per test), and received once a day (at 7:00 a.m. if light, or 7:00 p.m. if dark) either 2mg/kg racemic dextro- and levo-MPH mixture dissolved in saline solution (Ritalin, Novartis), or a saline intraperitoneal injection, for 28 days. We performed the treatment between PD25 - PD53 (in the case of the young rats) or PD60 - PD88 (for the adult rats). The selection of the MPH dose was based on previous findings that MPH doses of less than 5mg/kg intraperitoneal injection better reflect those used clinically in patients. 7 We submitted animals to behavioral tests in a different room from the one in which they were injected, two hours after the last injection.
3. Behavioral procedures
The elevated plus maze apparatus was made of wood and consisted of two opposed open arms (50 x 10 x 2cm) and two opposed closed arms (50 x 10 x 40cm), all facing a central platform (10 x 10cm), elevated 45cm from the floor. Each rat was placed in the center of an elevated plus maze facing one of the closed arms (n = 15 for each test condition). During a 5-minute test performed in a dark room illuminated with red light, we registered the number of entries into each arm and the time spent there.
The forced swimming test involved two individual exposures to a cylindrical tank with water in which rats could not touch the bottom of the tank or escape. The tank is made of transparent Plexiglas, 80cm high and 30cm in diameter, and filled with water (22-23°C) to a depth of 40cm. The water in the tank was changed after each rat. For the first exposure, rats were placed in the water for 15 minutes (the pre-test session). Twenty-four hours later, rats were placed in the water for 5 minutes (test session) and the length of time for which they remained immobile was recorded in seconds. We performed this test in a light room after 30 minutes' acclimatization. The animals had different behaviors during the light or dark cycle as expected (i.e. they were more active during the dark cycle).
4. Statistical analysis
The effects of cycle, treatment and age were analyzed using three-way analysis of variance (ANOVA) (equal variance and normaility tests p > 0.05). The model included as factors: cycle (light or dark), treatment (saline or MPH) and age (young or adult) followed by Holm-Sidak post-hoc test. We used Kruskal-Wallis one-way ANOVA on Ranks (because normality test result p < 0.05) to verify differences between experimental groups. Relevant mean differences were subsequently assessed using Dunn's multiple-comparison procedure. All analyses were performed using SigmaStat 3.1, and p < 0.05 indicated nominally statistical significance. The graph was presented in mean ±1.96*SE
The time spent in each arm on elevated plus maze was presented as a ratio (time spent ratio = time spent in the open arm/ time spent in the closed arm) - Figure 1. Three-way ANOVA revealed that cycle was a significant factor (F = 8.326; p = 0.005), while treatment (F = 0.019; p = 0.891) and age (F = 2.879; p = 0.093) were not significant. Holm-Sidak multiple comparison procedure showed cycle as a significant factor (difference of means = 0.288; t = 2.885; p = 0.0049). Kruskal-Wallis one-way ANOVA on Ranks showed differences in the mean values across the groups (H = 33.482; p = 0.00002). Therefore, we applied Dunn's test as a multiple comparison procedure. The Dunn's result indicated significant differences between adult rats treated with MPH during the light and the dark cycles (difference on Ranks = 36.291; Q = 3.417); and between young and adult rats during the light cycle after saline (difference on Ranks = 50.333; Q = 4.140) or MPH (difference on Ranks = 43.576; Q = 3.645) treatment (Figure 1).
The number of entries into each arm on elevated plus maze is presented as a ratio (number of entries ratio = number of entries into the open arm/ number of entries into the closed arm). Most of the groups presented ratios under 1.0, indicating that they entered the closed arms more often (the exception were adult rats during the dark cycle, whether treated with saline or MPH). Three-way ANOVA revealed that cycle was a significant factor (F = 9.060; p = 0.003), while treatment (F = 0.017; p = 0.895) and age (F = 0.869; p = 0.353) were not significant. Holm-Sidak multiple comparison procedure showed cycle as a significant factor (difference of means = 0.508; t = 3.010; p = 0.0034). Kruskal-Wallis one-way ANOVA on Ranks showed differences in the mean values across the groups (H = 18.987; p = 0.00823). Dunn's test was applied as a multiple comparison procedure, and the Dunn's test result indicated no significant differences between specific groups (p > 0.050) (data not shown).
The forced swimming test immobility time showed cycle (F = 2.373; p = 0.126), treatment (F = 0.289; p = 0.591) and age (F = 1.499; p = 0.223) as non-significant factors after three-way ANOVA, although we did find a significant interaction between cycle and age (F = 4.055; p = 0.046). Kruskal-Wallis one-way ANOVA on Ranks showed no significant differences (H = 9.660; p = 0.20867) (data not shown).
Our results have shown light/dark cycle to be an important factor in the anxiety-like behavior results. However, no major effects of the administration of MPH were seen on anxiety- and depressive-like behaviors, nor was any significant interaction among these three factors found in anxiety-like behavior. We observed a nominally significant interaction between light/dark cycle and age in the forced swimming test. A recent article has reported no differences in the elevated plus maze results after intraperitoneal MPH (2.0mg/kg, twice daily) administration. 8 Changes in anxiety- and depressive-like behaviors in rats were seen after MPH treatments with the same dose (2.0mg/kg) twice daily5 or with 5.0mg/kg twice daily. 9 Differential MPH effects observed across rat strains could explain these controversial findings. 10
There is convincing evidence that the effects in rats of the light/dark cycle undergo dramatic changes in the course of the animal's life, particularly during early ontogenetic development and in old age. 11 The light/dark cycle was a significant factor in the elevated plus maze results, while age and methylphenidate hydrochloride were not. Not many reports have evaluated the age-dependent expression of anxiety-related behaviors, and even fewer results are available regarding the influence of diurnal cycles. Both elevated12 and no changes13 have been shown to produce anxiety-like behaviors in older animals when compared with younger.
We have found a nominally significant interaction between light/dark cycle and age in the forced swimming test results. Kelliher et al. have explored diurnal influences on the forced swimming test results with no melatonin administration, and reported fewer depressive-like behaviors during the light phase in male Sprague-Dawley rats. 14 Results from studies using melatonin receptor agonists and melatonin administration have been controversial. 15 We administered MPH in the dark cycle at 7:00 p.m. It is relevant to mention that the peak of melatonin occurs at around 3 a.m. and the corticosterone peak occurs in the evening (around 7:00 p.m.). Both hormones may interfere with MPH behavioral effects.
In conclusion, our study evaluated together three important factors (light/dark cycle, age and MPH treatment) for anxiety- and depressive-like behaviors in rats. Our results have shown age and light/dark cycle as the most significant modulators of both behaviors. Further experiments are needed to shed more light on the role of those factors and the pharmacological mechanisms linked to anxiety- and depressive-like behaviors in rats. We would also like to reinforce the idea that the age of the rat, and the time of the day that experiments are performed, may very well alter the behavioral results of these two tests.
This research was supported by grants from JQ (Conselho Nacional de Pesquisa e Desenvolvimento, CNPq; Fundação de Amparo à Pesquisa do Estado de Santa Catarina, FAPESC; and Universidade do Extremo Sul Catarinense, UNESC). JQ is CNPq Research Fellows. RPS is holder of CIHR postdoctoral fellowship, SSV is holder of a Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) studentship, CMC is holder of a CNPq Studentship, and GZR is holder of a FAPESC studentship.
1. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl). 2008;197(1):1-11. [ Links ]
2. Gaytan O, Yang P, Swann A, Dafny N. Diurnal differences in sensitization to methylphenidate. Brain Res. 2000;864(1):24-39. [ Links ]
3. Bolaños CA, Willey MD, Maffeo ML, Powers KD, Kinka DW, Grausam KB, Henderson RP. Antidepressant treatment can normalize adult behavioural deficits induced by early-life exposure to methylphenidate. Biol Psychiatry. 2008;63(3):309-16. [ Links ]
4. Liebsch G, Linthorst AC, Neumann ID, Reul JM, Holsboer F, Landgraf R. Behavioural, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high- and low-anxiety-related behaviour. Neuropsychopharmacology. 1998;19(5):381-96. [ Links ]
5. Bolaños CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ. Methylphenidate treatment during pre- and periadolescence alters behavioural responses to emotional stimuli at adulthood. Biol Psychiatry. 2003;54(12):1317-29. [ Links ]
6. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl). 2005;177(3):245-55. [ Links ]
7. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, Dewey SL. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther. 2000;295(1):51-7. [ Links ]
8. Vendruscolo LF, Izidio GS, Takahashi RN, Ramos A. Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol. 2008;19(1):21-7. [ Links ]
9. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007;27(27):7196-207. [ Links ]
10. Bizot JC, Chenault N, Houzé B, Herpin A, David S, Pothion S, Trovero F. Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacology (Berl). 2007;193(2):215-23. [ Links ]
11. Weinert D, Sitka U, Minors DS, Waterhouse JM. The development of circadian rhythmicity in neonates. Early Hum Dev. 1994;36(2):117-26. [ Links ]
12. Imhof JT, Coelho ZM, Schmitt ML, Morato GS, Carobrez AP. Influence of gender and age on performance of rats in the elevated plus maze apparatus. Behav Brain Res. 1993;56(2):177-80. [ Links ]
13. Varlinskaya EI, Spear LP. Acute effects of ethanol on social behaviour of adolescent and adult rats: role of familiarity of the test situation. Alcohol Clin Exp Res. 2002;26(10):1502-11. [ Links ]
14. Kelliher P, Connor TJ, Harkin A, Sanchez C, Kelly JP, Leonard BE. Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. Physiol Behav. 2000;69(4-5):531-9. [ Links ]
15. Shaji AV, Kulkarni SK. Central nervous system depressant activities of melatonin in rats and mice. Indian J Exp Biol. 1998;36(3):257-63. [ Links ]
Laboratório de Neurociências, PPGCS, UNASAU, Universidade do Extremo Sul Catarinense
88806-000 Criciúma, SC, Brazil
Fax: (+55 48) 3443-4817
Submitted: August 6, 2009
Accepted: March 19, 2010